ATSUSI OONO

Last Updated :2024/02/02

Affiliations, Positions
Graduate School of Biomedical and Health Sciences(Medicine), Assistant Professor
E-mail
atsushi-ohiroshima-u.ac.jp

Basic Information

Academic Degrees

  • Hiroshima University

Educational Activity

  • [Bachelor Degree Program] School of Medicine : Program of Medicine : Medicine
  • [Doctoral Program] Graduate School of Biomedical and Health Sciences : Division of Biomedical Sciences : Program of Medicine

Research Fields

  • Medicine,dentistry, and pharmacy;Clinical internal medicine;Gastroenterology

Research Keywords

  • Liver cancer, Viral hepatitis

Affiliated Academic Societies

  • the Japan Society of Hepatology
  • the Japanese Society of Internal Medicine
  • the Japanese Society of Gastroenterology
  • Japan Gastroenterological Endoscopy Society

Educational Activity

Course in Charge

  1. 2023, Undergraduate Education, Year, Clinical diagnosis and treatment I
  2. 2023, Undergraduate Education, Intensive, Introduction to clinical clerkship
  3. 2023, Undergraduate Education, Intensive, Practice of Medicine I
  4. 2023, Undergraduate Education, Intensive, Practice of Medicine II
  5. 2023, Undergraduate Education, First Semester, Internal Medicine I

Research Activities

Academic Papers

  1. Sodium-glucose cotransporter-2 inhibitors improve FibroScan-aspartate aminotransferase scores in patients with nonalcoholic fatty liver disease complicated by type 2 diabetes, EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 35(9), 989-996, 202309
  2. Successful Lenvatinib Re-challenge following Atezolizumab Plus Bevacizumab Combination Therapy Failure for Unresectable Hepatocellular Carcinoma, INTERNAL MEDICINE, 62(12), 1771-1774, 2023
  3. Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study, BMC GASTROENTEROLOGY, 23(1), 20230628
  4. Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein, CANCERS, 15(8), 202304
  5. Hepatitis B Virus (HBV) Upregulates TRAIL-R3 Expression in Hepatocytes Resulting in Escape From Both Cell Apoptosis and Suppression of HBV Replication by TRAIL, JOURNAL OF INFECTIOUS DISEASES, 227(5), 686-695, 20230301
  6. Effectiveness of Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma-Consideration of the Locations of Target Lesions, CANCERS, 15(3), 202302
  7. Evaluation of atezolizumab plus bevacizumab combination therapy for hepatocellular carcinoma using contrast-enhanced ultrasonography, JOURNAL OF MEDICAL ULTRASONICS, 50(1), 57-62, 202301
  8. Low-Dose Alcohol-Induced Inhibition of Mouse Orthotopically Transplanted Tumors Is Associated with T-Cell Response, PATHOBIOLOGY, 90(1), 22-30, 202301
  9. Hepatic venous pressure gradient after balloon-occluded retrograde transvenous obliteration and liver stiffness measurement predict the prognosis of patients with gastric varices, BMC GASTROENTEROLOGY, 22(1), 20221222
  10. Proteo-genomic characterization of virus-associated liver cancers reveals potential subtypes and therapeutic targets, NATURE COMMUNICATIONS, 13(1), 20221029
  11. Comprehensive analysis of full-length transcripts reveals novel splicing abnormalities and oncogenic transcripts in liver cancer, PLOS GENETICS, 18(8), 202208
  12. ★, The presence of vessels encapsulating tumor clusters is associated with an immunosuppressive tumor microenvironment in hepatocellular carcinoma, INTERNATIONAL JOURNAL OF CANCER, 151(12), 2278-2290, 20221215
  13. Analysis of Lenvatinib's Efficacy against Intermediate-Stage Unresectable Hepatocellular Carcinoma, CANCERS, 14(20), 202210
  14. ★, Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development, GASTROENTEROLOGY, 162(4), 1210-1225, 202204
  15. The effect of the skin-liver capsule distance on the accuracy of ultrasound diagnosis for liver steatosis and fibrosis, JOURNAL OF MEDICAL ULTRASONICS, 49(3), 443-450, 202207
  16. Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease, SCIENCE TRANSLATIONAL MEDICINE, 14(650), 20220622
  17. HBV upregulates TRAIL-R3 expression in hepatocytes for escaping both cell apoptosis and suppression of their replication by TRAIL, J Infect Dis, 2022
  18. Genomic characterization of early-stage esophageal squamous cell carcinoma in a Japanese population, Oncotarget, 10(41), 4139-4148, 2019
  19. Pathological Complete Response to Lenvatinib after Failure of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma, Liver Cancer, 202111
  20. ★, Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development, 162(4), 1210-1225, 202204
  21. Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease, Sci Transl Med, 14, 202206
  22. Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study, BMC GASTROENTEROLOGY, 22(1), 20220602
  23. Construction of an anti-hepatitis B virus preS1 antibody and usefulness of preS1 measurement for chronic hepatitis B patients Anti-HBV PreS1 antibody, JOURNAL OF INFECTION, 84(3), 391-399, 202203
  24. Benign Recurrent Intrahepatic Cholestasis Type 1 with Novel Nonsense Mutations in the ATP8B1 Gene, CASE REPORTS IN GASTROENTEROLOGY, 16(1), 110-115, 2022
  25. ★, Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy, Cellular and Molecular Gastroenterology and Hepatology, 1(5), 516-534, 2015
  26. ★, Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients, J Hepatol, 57((3),), 508-514, 2012
  27. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 31(5), 1009-1015, 201605
  28. Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case report, HEPATOLOGY RESEARCH, 46(9), 944-948, 201608
  29. Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection, JOURNAL OF GASTROENTEROLOGY, 51(11), 1073-1080, 201611
  30. Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C, HEPATOLOGY RESEARCH, 46(12), 1256-1263, 201611
  31. The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients, JOURNAL OF GASTROENTEROLOGY, 52(3), 366-375, 201703
  32. Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals, BMC MEDICINE, 15, 20170314
  33. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy., J Gastroenterol. 2017 May 4. doi: 10.1007/s00535-017-1348-8., 20170504
  34. The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy, PLOS ONE, 12(8), 20170810
  35. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy, JOURNAL OF GASTROENTEROLOGY, 53(1), 107-118, 201801
  36. Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease, JOURNAL OF GASTROENTEROLOGY, 53(2), 269-280, 201802
  37. Serial profiling of circulating tumor DNA for optimization of anti-VEGF chemotherapy in metastatic colorectal cancer patients, INTERNATIONAL JOURNAL OF CANCER, 142(7), 1418-1426, 20180401
  38. Cell type-specific pharmacological kinase inhibition for cancer chemoprevention, NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 14(2), 317-325, 201802
  39. miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis, GUT, 67(5), 953-962, 201805
  40. ★, Persisting risk of hepatocellular carcinoma after hepatitis C virus cure monitored by a liver transcriptome signature, 66(4), 1344-1346, 20170408
  41. Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures, JOURNAL OF GASTROENTEROLOGY, 54(3), 291-296, 201903
  42. HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response, GASTROENTEROLOGY, 156(8), 2313-+, 201906
  43. Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes, CANCER CELL, 35(6), 932-+, 20190610
  44. Comparison of intracellular responses between HBV genotype A and C infection in human hepatocyte chimeric mice, JOURNAL OF GASTROENTEROLOGY, 54(7), 650-659, 201907
  45. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice, . J Gen Virol., 100(7), 1123-1131, 201907
  46. Genomic landscape of epithelium with low-grade atypia on gastric cancer after Helicobacter pylori eradiation therapy, JOURNAL OF GASTROENTEROLOGY, 54(10), 907-915, 201910
  47. eVIDENCE: a practical variant filtering for low-frequency variants detection in cell-free DNA, SCIENTIFIC REPORTS, 9, 20191022
  48. Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis, BMC GASTROENTEROLOGY, 19(1), 20191024
  49. Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy, CLINICAL JOURNAL OF GASTROENTEROLOGY, 13(2), 267-270, 202004
  50. Classification of primary liver cancer with immunosuppression mechanisms and correlation with genomic alterations, EBIOMEDICINE, 53, 202003
  51. Genomic Characterization of Non-Invasive Differentiated-Type Gastric Cancer in the Japanese Population, CANCERS, 12(2), 202002
  52. ★, Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib, THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 12, 202005
  53. Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab, HEPATOLOGY RESEARCH, 50(7), 885-888, 202007
  54. Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma, CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 11, 202005
  55. Risk factors for histological progression of non-alcoholic steatohepatitis analyzed from repeated biopsy cases, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 35(8), 1412-1419, 202008
  56. Complete response to pembrolizumab in advanced hepatocellular carcinoma with microsatellite instability, CLINICAL JOURNAL OF GASTROENTEROLOGY, 13(5), 867-872, 202010
  57. Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients, HEPATOLOGY RESEARCH, 50(11), 1222-1233, 202011
  58. Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis, HEPATOLOGY RESEARCH, 50(11), 1234-1243, 202011
  59. Stromal reaction inhibitor and immune-checkpoint inhibitor combination therapy attenuates excluded-type colorectal cancer in a mouse model, CANCER LETTERS, 498, 111-120, 20210201
  60. Abatacept treatment for patients with severe acute hepatitis caused by hepatitis B virus infection-Pilot study, JOURNAL OF VIRAL HEPATITIS, 28(2), 400-409, 202102
  61. Signal Activation of Hepatitis B Virus-Related Hepatocarcinogenesis by Up-regulation of SUV39h1, JOURNAL OF INFECTIOUS DISEASES, 222(12), 2061-2070, 20201215
  62. yRibavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy, JOURNAL OF MEDICAL VIROLOGY, 92(2), 210-218, 202002
  63. Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 559, 78-83, 20210625
  64. Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma, GUT, 70(1), 157-169, 202101
  65. In vitro analysis of hepatic stellate cell activation influenced by transmembrane 6 superfamily 2 polymorphism, MOLECULAR MEDICINE REPORTS, 23(1), 202101
  66. ★, Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib, JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 40(1), 20210626
  67. Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study, BMC GASTROENTEROLOGY, 21(1), 20210731
  68. Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients, JOURNAL OF VIRAL HEPATITIS, 28(9), 1304-1311, 202109
  69. Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma, CANCERS, 14(2), 202201

Invited Lecture, Oral Presentation, Poster Presentation

  1. Circulating cell free tumor DNA analysis in advanced hepatocellular carcinoma treated with Lenvatinib,, Atsushi Ono, Yasutoshi Fujii, C. Nelson Hayes, Masami Yamauchi, Yuji Teraoka, Hatsue Fujino, Takashi Nakahara, Eisuke Murakami, Daiki Miki, Tomokazu Kawaoka, Michio Imamura, Wataru Okamoto, Kazuaki Chayama and Hiroshi Aikata, 2021/11/12, Without Invitation, English
  2. A COMPREHENSIVE ANALYSIS OF A WIDE RANGE OF LIVER DISEASES BY 16S rRNA SEQUENCING REVEALS CHARACTERISTIC PATTERNS OF GUT MICROBIOTA IN EACH ETIOLOGY, Daiki Miki, Yumi Shimomura, Nelson Hayes, Hiromi Abe-Chayama, Hatsue Fujino, Maiko Numba, Takashi Nakahara, Atsushi Ono, Eisuke Murakami, Masami Yamauchi, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Hiroshi Aikata, Grace Naswa Makokha, Tatsuhiko Tsunoda, Kazuaki Chayama, The Liver Meeting 2019, 2019/11/11, Without Invitation, English, American Association for the Study of Liver Diseases, Boston, United State
  3. INDEPENDENT IMPACT OF POLYMORPHISM IN IRF5 AS WELL AS STAT4 ON HBV-RELATED HEPATOCARCINOGENESIS, Daiki Miki, Masataka Tsuge, Hiromi Abe-Chayama, Nelson Hayes, Hatsue Fujino, Grace Naswa Makokha, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Tomokazu Kawaoka, Akira Hiramatsu, Michio Imamura, Hiroshi Aikata, Tatsuhiko Tsunoda, Kazuaki Chayama, The Liver Meeting 2019, 2019/11/11, Without Invitation, English, American Association for the Study of Liver Diseases, Boston, United State
  4. ASSOCIATION OF FNDC5, PNPLA3 AND TM6SF2 POLYMORPHISMS WITH HEPATIC STEATOSIS IN NAFLD PATIENTS, Daiki Miki, Takashi Nakahara, Eisuke Murakami, Hiromi Abe-Chayama, Hatsue Fujino, Atsushi Ono, Masami Yamauchi, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Hiroshi Aikata, Nelson Hayes, Grace Naswa Makokha, Tatsuhiko Tsunoda, Kazuaki Chayama, The Liver Meeting 2019, 2019/11/10, Without Invitation, English, American Association for the Study of Liver Diseases, Boston, USA
  5. DIFFERENTIAL EFFECTS OF HOST GENETIC FACTORS ON HCV PERSISTENCE ACCORDING TO HCV GENOTYPES, Daiki Miki, Tomokazu Kawaoka, Nelson Hayes, Hiromi Abe-Chayama, Hatsue Fujino, Grace Naswa Makokha, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Hiroshi Aikata, Tatsuhiko Tsunoda, Kazuaki Chayama, The Liver Meeting 2019, 2019/11/10, Without Invitation, English, American Association for the Study of Liver Diseases
  6. RESISTANCE ANALYSIS FOR GLECAPREVIR AND PIBRENTASVIR ON GENOTYPE 1b HEPATITIS C VIRUS INFECTION IN SUBGENOMIC REPLICON SYSTEMS AND HUMAN HEPATOCYTE TRANSPLANTED MICE, Mitsutaka Osawa, Michio Imamura, Takuro Uchida, Yuji Teraoka, Hatsue Fujino, Takashi Nakahara, Atsushi Ono, Eisuke Murakami, Tomokazu Kawaoka, Daiki Miki, Masataka Tsuge, Akira Hiramatsu, Hiromi Abe-Chayama, Nelson Hayes, Grace Naswa Makokha, Hiroshi Aikata, Yuji Ishida, Chise Tateno, Yohei Miyayama, Makoto Hijikata, Kazuaki Chayama, The Liver Meeting 2019, The Liver Meeting 2019, 2019/11/10, Without Invitation, English, American Association for the Study of Liver Diseases, Boston, USA
  7. TUMOR AND BLOOD FGFR4 LEVELS PREDICT THE EFFICACY OF LENVATINIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA, Masami Yamauchi, Atsushi Ono, Haruna Hatooka, Kenichiro Kodama, Peiyi Zhang, Yuji Teraoka, Kei Morio, Hatsue Fujino, Takashi Nakahara, Eisuke Murakami, Daiki Miki, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Clair Nelson Hayes, Hiroshi Aikata, Kazuaki Chayama, The Liver Meeting 2019, 2019/11/09, Without Invitation, English, American Association for the Study of Liver Diseases
  8. PERMISSION OF HEPATITIS B VIRUS INFECTION IN Jak3KORag2KO MOUSE, Yuji Teraoka, Michio Imamura, Takuro Uchida, Kazuki Ohya, Mitsutaka Osawa, Kei Morio, Hatsue Fujino, Takashi Nakahara, Atsushi Ono, Eisuke Murakami, Masami Yamauchi, Tomokazu Kawaoka, Masataka Tsuge, Daiki Miki, Akira Hiramatsu, Hiromi Abe-Chayama, Nelson Hayes, Yuji Ishida, Chise Tateno, Hiroshi Aikata, Kazuaki Chayama, The Liver Meeting 2019, 2019/11/09, Without Invitation, English, American Association for the Study of Liver Diseases, Boston, USA
  9. GENETIC POLYMORPHISM OF IP-10, NOT IFNL4 OR HLA-DPS, AFFECTS LIVER INFLAMMATION IN CHRONIC HEPATITIS B PATIENTS, Daiki Miki, Masataka Tsuge, Hiromi Abe-Chayama, Nelson Hayes, Hatsue Fujino, Grace Naswa Makokha, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Tomokazu Kawaoka, Akira Hiramatsu, Michio Imamura, Hiroshi Aikata, Tatsuhiko Tsunoda, Kazuaki Chayama, The Liver Meeting 2019, 2019/11/08, Without Invitation, English, American Association for the Study of Liver Diseases, Boston, USA
  10. EXPLORATORY ANALYSIS OF BIOMARKERS ASSOCIATED WITH CLINICAL OUTCOMES OF LENVATINIB IN HEPATOCELLULAR CARCINOMA, Atsushi Ono, Hiroshi Aikata, Masami Yamauchi, Kenichiro Kodama, Daiki Miki, Waka Ohishi, Yuji Teraoka, Hatsue Fujino, Takashi Nakahara, Eisuke Murakami, Tomokazu Kawaoka, Hiromi Abe-Chayama, Masataka Tsuge, Michio Imamura, Clair Nelson Hayes, Kazuaki Chayama, The Liver Meeting 2019, 2019/11/08, Without Invitation, English, American Association for the Study of Liver Diseases, Boston, USA
  11. The SNP allele corresponding to higher IRF5 expression reduces susceptibility to HBV-related hepatocellular carcinoma, Daiki Miki, Masataka Tsuge, Masami Yamauchi, Atsushi Ono, Hiroshi Aikata, Tatsuhiko Tsunoda, Kazuaki Chayama, The 78th Annual Meeting of the Japanese Cancer Association, 2019/09/26, Without Invitation, English, Japanese Cancer Association, Kyoto, Japan
  12. Multiple genetic factors affecting nonalcoholic fatty liver disease and nonalcoholic steatohepatitis-related hepatocellular carcinoma in the Japanese population, Daiki Miki, Yuichi Hiyama, Atsushi Ono, Masami Yamauchi, Masataka Tsuge, Hiroshi Aikata, Tatsuhiko Tsunoda, Kazuaki Chayama, 11th AACR-JCA Joint Conference, 2019/02/10, Without Invitation, English, American Association for Cancer Research, Japanese Cancer Association, Maui, Hawaii, USA
  13. Association of TLL1 Polymorphism with Development of Hepatocellular Carcinoma after Hepatitis C Virus Eradication and Fibrosis Severity, Daiki Miki, Tomokazu Kawaoka, Yuko Nagaoki, Nelson Hayes, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Hiroshi Aikata, Hiromi Abe-Chayama, Hidenori Ochi, Tatsuhiko Tsunoda, Kazuaki Chayama, The Liver Meeting 2018, 2018/11/10, Without Invitation, English, American Association for the Study of Liver Diseases
  14. Serum HMGB1 concentrations is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy, The Liver Meeting 2017, 2017/10/22, Without Invitation, English, other
  15. Hepatic stellate cell-targeted pharmacological EGFR inhibition for HCC chemoprevention, The Liver Meeting 2017, 2017/10/20, Without Invitation, English, other
  16. Serial profiling of circulating tumor DNA identifies biomarkers for anti-VEGF chemotherapy in mCRC patients, Yamauchi, Masami; Chayama, Kazuaki; Urabe, Yuji; Ono, Atsushi; Ochi, Hidenori; Miki, Daiki, 2017 Annual Meeting of the Japanese-Society-of-Medical-Oncology, 2017/07, Without Invitation, Japanese, Japanese-Society-of-Medical-Oncology
  17. Japanese genetic study could not suggest the importance of the NTCP locus for HBV persistence, Miki D, Ochi H, Hayes CN, Abe H, Akamatsu S, Ono A, Nakahara T, Zhang Y, Masaki K, Fujino H, Miyaki E, Kan H, Uchida T, Hiraga N, Tsuge M, Kawaoka T, Imamura M, Kawakami Y, Aikata H, Chayama K, The 25th Conference of the Asian Pacific Association for the Study of the Liver, 2016/02/22, Without Invitation, English, Asian Pacific Association for the Study of the Liver (APASL)
  18. The relationship between hepatocellular carcinoma development and reduced expression levels of the major germline genotype of PROSC, which is frequently deleted in hepatocellular carcinoma, Miki, Daiki; Ochi, Hidenori; Hayes, C. Nelson; Abe, Hiromi; Akamatsu, Sakura; Ono, Atsushi; Nakahara, Takashi; Zhang, Yizhou; Masaki, Keiichi; Fujino, Hatsue; Miyaki, Eisuke; Kan, Hiromi; Uchida, Takuro; Hiraga, Nobuhiko; Tsuge, Masataka; Kawaoka, Tomokazu; Imamura, Michio; Kawakami, Yoshiiku; Aikata, Hiroshi; Chayama, Kazuaki, 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), 2015/11, Without Invitation, English, American-Association-for-the-Study-of-Liver-Diseases (AASLD)
  19. Circulating tumor DNA analysis for liver cancers and its usefulness as a liquid biopsy, Ono A, Hayes CN, Uchida T, Kan H, Masaki K, Nakahara T, Miki D, Kawaoka T, Tsuge M, Hiraga N, Imamura M, Kawakami Y, Aikata H, Ochi H, Abe H, Nakagawa H, Chayama K, AASLD the LIVER MEETING, San Francisco, CA, November 2015., 2015, Without Invitation, English
  20. The IL28B SNP has a stronger regulatory effect on the expression of OAS1 than a nearby SNP located downstream of OAS1 in chronic HCV patients, Miki, Daiki; Abe, Hiromi; Hayes, C. Nelson; Ochi, Hidenori; Kawaoka, Tomokazu; Akamatsu, Sakura; Ono, Atsushi; Nakahara, Takashi; Seki, Noriaki; Murakami, Eisuke; Zhang, Yizhou; Uchida, Takuro; Honda, Yohji; Masaki, Keiichi; Kan, Hiromi; Tsuge, Masataka; Hiraga, Nobuhiko; Imamura, Michio; Kawakami, Yoshiiku; Aikata, Hiroshi; Kubo, Michiaki; Chayama, Kazuaki, 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, 2014/11, Without Invitation, English
  21. A single amino acid substitution in HLA-DQB1 as well as an IFNL4 variant strongly affect susceptibility to chronic hepatitis C, Miki, Daiki; Ochi, Hidenori; Takahashi, Atsushi; Hayes, C. Nelson; Urabe, Yuji; Abe, Hiromi; Ono, Atsushi; Akamatsu, Sakura; Nakahara, Takashi; Seki, Noriaki; Murakami, Eisuke; Zhang, Yizhou; Uchida, Takuro; Honda, Yohji; Yoshimi, Satoshi; Kobayashi, Tomoki; Masaki, Keiichi; Kan, Hiromi; Kawaoka, Tomokazu; Tsuge, Masataka; Hiraga, Nobuhiko; Imamura, Michio; Kawakami, Yoshiiku; Aikata, Hiroshi; Takahashi, Shoichi; Akuta, Norio; Suzuki, Fumitaka; Ikeda, Kenji; Kumada, Hiromitsu; Karino, Yoshiyasu; Toyota, Joji; Tsunoda, Tatsuhiko; Kubo, Michiaki; Kamatani, Naoyuki; Nakamura, Yusuke; Chayama, Kazuaki, 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, 2014/11, Without Invitation, English
  22. Two microRNA polymorphisms are associated with hepatitis B virus-related but not hepatitis C virus-related hepatocellular carcinoma in the Japanese population, Miki, Daiki; Ochi, Hidenori; Hayes, C. Nelson; Abe, Hiromi; Kawaoka, Tomokazu; Ono, Atsushi; Akamatsu, Sakura; Nakahara, Takashi; Seki, Noriaki; Murakami, Eisuke; Zhang, Yizhou; Uchida, Takuro; Honda, Yohji; Masaki, Keiichi; Kan, Hiromi; Tsuge, Masataka; Hiraga, Nobuhiko; Imamura, Michio; Kawakami, Yoshiiku; Aikata, Hiroshi; Kubo, Michiaki; Chayama, Kazuaki, 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, 2014/11, Without Invitation, Japanese
  23. Analysis Of Circulating Tumor DNA In Hepatocellular Carcinoma, International Liver Cancer Association 8th Annual Conference, 5–7 September 2014, Kyoto, Japan, 2014/09/05, Without Invitation, English
  24. Analysis Of Circulating Tumor DNA In Hepatocellular Carcinoma, Ono A, Aikata H, Chayama K, International Liver Cancer Association 8th Annual Conference, 2014, Without Invitation, English
  25. Antiviral effect of tenofovir disoproxil fumarate on drug-resistant HBV clones and different susceptibility between HBV genotype A and C, Murakami, Eisuke; Tsuge, Masataka; Hiraga, Nobuhiko; Kawaoka, Tomokazu; Ono, Atsushi; Miki, Daiki; Abe, Hiromi; Imamura, Michio; Aikata, Hiroshi; Ochi, Hidenori; Hayes, C. Nelson; Chayama, Kazuaki, 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, 2013/11, Without Invitation, English
  26. Exploratory analysis of biomarkers associated with clinical outcomes in advanced HCC patients receiving lenvatinib, The 79th Annual Meeting of the Japanese Cancer Association, Without Invitation, Japanese
  27. Germline variants of highly point-mutated genes in hepatocellular carcinoma do not have strong effects on HCV-related hepatocarcinogenesis, Miki, Daiki; Ochi, Hidenori; Hayes, C. Nelson; Ono, Atsushi; Akamatsu, Sakura; Urabe, Yuji; Masaki, Keiichi; Abe, Hiromi; Kawaoka, Tomokazu; Nakahara, Takashi; Seki, Noriaki; Murakami, Eisuke; Zhang, Yizhou; Uchida, Takuro; Honda, Yohji; Kan, Hiromi; Tsuge, Masataka; Hiraga, Nobuhiko; Imamura, Michio; Kawakami, Yoshiiku; Aikata, Hiroshi; Kubo, Michiaki; Chayama, Kazuaki, 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Without Invitation, Japanese

External Funds

Acceptance Results of Competitive Funds

  1. 2022/04/01, 2024/03/31
  2. Grants-in-Aid for Scientific Research, 2020, 2021
  3. KAKENHI(Grant-in-Aid for Young Scientists (B)), 2017, 2019

Social Activities

History as Peer Reviews of Academic Papers

  1. 2023, Scientific Reports, Others, 1
  2. 2023, Cancer Reports, Others, Reviewer, 1
  3. 2022, Liver Internationalnternational, Others
  4. 2022, Cancer Science, Others, Reviewer, 1
  5. 2021, Kanzo, Others, Reviewer, 3
  6. 2021, Frontiers in Immunology, Others, Reviewer, 1
  7. 2021, Journal of gastroenterology, Others, Reviewer, 1
  8. 2021, Journal of Hepatocellular Carcinoma, Others, Reviewer, 1
  9. 2021, Expert Review of Gastroenterology & Hepatology, Others, Reviewer, 1
  10. 2022, Kanzo, Others, Reviewer, 6
  11. 2022, Liver Cancer, Others, Reviewer, 1
  12. 2022, Journal of Hepatocellular carcinoma, Others, Reviewer, 1
  13. 2022, Expert Review of Gastroenterology & Hepatology, Others, Reviewer, 1
  14. 2022, Clinical Gastroenterology and Hepatology, Others, Reviewer, 1
  15. 2022, Cancers, Others, 1
  16. 2020, Journal of Gastroenterology, Others, 1
  17. 2020, Genome Medicine, Others, 1
  18. 2020, Cancer Management and Research, Others, reviewer, 1
  19. 2021, Computational and Structural Biotechnology Journal, Others, reviewer, 1
  20. 2021, Cancer Management and Research, Others, reviewer, 1